Form 4: Dermata Therapeutics CFO Acquires 20,000 Stock Options

Dermata Therapeutics' CFO, Kyri K. Van Hoose, was granted 20,000 stock options on January 13, 2025.

Summary

• Kyri K. Van Hoose, the SVP and CFO of Dermata Therapeutics, acquired 20,000 stock options on January 13, 2025.
• The options have an exercise price of $1.38 per share.
• The options vest 25% after 12 months from the grant date, and the remaining 75% vest in 36 equal monthly installments starting after the first year.
• The options expire on January 12, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of stock options to the CFO aligns their interests with the long-term success of the company.
• The vesting schedule encourages the CFO's continued service and contribution to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 25% after one year and the remaining 75% over the following three years is a typical vesting structure for stock options.
• The exercise price of $1.38 is specific to Dermata Therapeutics and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• The stock option grant may have a positive impact on shareholders by incentivizing the CFO to improve company performance.
• The grant has a positive impact on the CFO's compensation.

Key Dates

Keywords

stock options, executive compensation, insider trading, Dermata Therapeutics, DRMA, CFO, Kyri K. Van Hoose